Literature DB >> 7156904

Ulnar neuropathy at the elbow treated with decompression. A clinical and electrophysiological investigation.

H Lugnegård, L Juhlin, B Y Nilsson.   

Abstract

Forty-four patients with ulnar neuropathy confined to the elbow region were operated with simple decompression. The operation was usually performed more than six months after the debut of symptoms. At follow-up earliest six months postoperatively 89% of the patients had improved and 39% recovered completely. An improvement in EMG activity and/or nerve conduction velocity was seen in 89% of the patients tested pre- and postoperatively. The validity of nerve compression, epineurial fibrosis and other factors of possible prognostic significance such as age, duration of symptoms and electrophysiological findings are discussed. Since the results of simple decompression of the ulnar nerve were similar to those obtained in a previous study of transposition, the former method is recommended as the standard procedure.

Entities:  

Mesh:

Year:  1982        PMID: 7156904     DOI: 10.3109/02844318209006591

Source DB:  PubMed          Journal:  Scand J Plast Reconstr Surg        ISSN: 0036-5556


  4 in total

1.  Anatomical basis for a technique of ulnar nerve transposition.

Authors:  P C Amadio
Journal:  Surg Radiol Anat       Date:  1986       Impact factor: 1.246

2.  A clinical and electrophysiological investigation of anterior transposition for ulnar neuropathy at the elbow.

Authors:  R J Friedman; T P Cochran
Journal:  Arch Orthop Trauma Surg       Date:  1987

3.  Posttraumatic ulnar neuropathy versus non-traumatic cubital tunnel syndrome: clinical features and response to surgery.

Authors:  C Barrios; C Ganoza; J de Pablos; J Cañadell
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

4.  Effects of tendon transfer to restore index finger abduction for severe cubital tunnel syndrome.

Authors:  Shingo Nobuta; Katsumi Sato; Kenji Kanazawa; Masahito Hatori; Eiji Itoi
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.